---
title: "keynote-689"
date: "2024-09-28"
tags:
  - building
---

> [!NOTE]
> ðŸŒ± created from: [[treatmentâ€“curative-hnscc]]

# keynote-689

The ongoing randomized, open-label, phase 3 KEYNOTE-689 trial is evaluating the efficacy and safety of neoadjuvant and adjuvant pembrolizumab in combination with standard-of-care (radiotherapy Â± cisplatin) in patients with previously untreated, resectable, locally advanced head and neck squamous cell carcinoma, with dual primary endpoints of major pathological response and event-free survival.
